Peyronie's disease response to intralesional collagenase clostridium histolyticum therapy is independent of baseline testosterone

Andrology. 2024 May;12(4):830-834. doi: 10.1111/andr.13532. Epub 2023 Sep 27.

Abstract

Background: Testosterone plays an important role in collagen metabolism, transforming growth factor-β1 expression, and wound healing, which are all critical factors in pathogenesis of Peyronie's disease. Some clinical studies have suggested an association between Peyronie's disease and hypogonadism.

Objective: We sought to investigate whether baseline total testosterone levels influence response to intralesional collagenase clostridium histolyticum in Peyronie's disease.

Methods: A retrospective review of patients receiving collagenase clostridium histolyticum injections with available total testosterone levels within 1 year of initial injection was conducted at a single institution. Baseline demographics, hypogonadal status, total testosterone, number of collagenase clostridium histolyticum cycles, and pre- and post-treatment degrees of curvature were collected. Hypogonadism was defined as total testosterone <300 ng/dL.

Results and discussion: Thirty-six men were included with mean age of 58.2 years (SD 10.4) and mean body mass index 26.8 (SD 3.2). The mean total testosterone was 459.2 ng/dL (SD 144.0), and four (11.1%) were hypogonadal. Mean pre-treatment curvature was 47.6°, and mean post-treatment curvature was 27.8°, with mean improvement of 19.9° (40.1%). Hypogonadal status was not significantly associated with more severe curvature, 46.4° among hypogonadal men as to 57.5° among eugonadal men (p = 0.32). On linear regression analysis, total testosterone did not significantly predict improvement in degrees (β = -0.02; R2 = 0.06; p = 0.14) or percent (β = 0.0; R2 = 0.05; p = 0.18). Improvement in neither degrees nor percent differed significantly by hypogonadal status (p = 0.41 and 0.82, respectively). The cycle number did significantly predict greater improvement in curvature on both univariate and multivariate analyses (β = 5.7; R2 = 0.34; p < 0.01).

Conclusion: Neither total testosterone nor hypogonadism is associated with a degree of improvement after collagenase clostridium histolyticum treatment.

Keywords: Peyronie's disease; hypogonadism; intralesional collagenase clostridium histolyticum; testosterone.

MeSH terms

  • Humans
  • Hypogonadism* / drug therapy
  • Hypogonadism* / pathology
  • Injections, Intralesional
  • Male
  • Microbial Collagenase / therapeutic use
  • Middle Aged
  • Penile Induration* / drug therapy
  • Penile Induration* / pathology
  • Penis / pathology
  • Testosterone / therapeutic use
  • Testosterone Congeners
  • Treatment Outcome

Substances

  • Microbial Collagenase
  • Testosterone
  • Testosterone Congeners